Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL170994 | 0.86 | CYP1A2 (0.32) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL3503898 | 0.85 | MEN1 (0.34) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL6469433 | 0.79 | TDP1 (0.33) | — | |
| SCHEMBL192296 | 0.79 | MEN1 (0.39) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL8468329 | 0.78 | MEN1 (0.30) | MEN1KMT2ACYP1A2HRH1 | |
| SCHEMBL1260630 | 0.77 | MEN1 (0.33) | MEN1KMT2ACYP1A2HRH1LMNA | |
| SCHEMBL14739090 | 0.76 | MEN1 (0.35) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL1692410 | 0.76 | MEN1 (0.37) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL1260408 | 0.75 | TSHR (0.37) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL14739986 | 0.75 | GABBR2 (0.36) | MEN1KMT2ACYP1A2HRH1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1625 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122011871-A | Biosensor polymer outer membrane and preparation method thereof | 深圳希沃康医疗科技有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-117120020-A | Implantable medical device for delivery of nucleic acid encapsulated particles | 塞拉尼斯伊娃高性能聚合物公司 | 2023-11-24 | — | — | CN | claimed |
| US-20220389160-A1 | EFFECTIVE INTRANASAL DELIVERY TO BRAIN | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2022-12-08 | — | — | US | claimed |
| CN-114641517-A | Effective brain delivery technology by nasal administration | 汉阳大学校产学协力团 | 2022-06-17 | — | — | CN | claimed |
| US-20220168325-A1 | METHODS TO PROMOTE CEREBRAL BLOOD FLOW IN THE BRAIN | THE UNIVERSITY OF VERMONT | 2022-06-02 | — | — | US | claimed |
| US-11300572-B2 | Methods and systems for producing nanolipoprotein particles | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2022-04-12 | — | — | US | claimed |
| US-20220096643-A1 | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates And Their Preparation | KODIAK SCIENCES INC (US) | 2022-03-31 | — | — | US | claimed |
| US-10864169-B2 | Conjugated polymer nanoparticles and manufacturing method thereof | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2020-12-15 | — | — | US | claimed |
| WO-2020198037-A1 | METHODS TO PROMOTE CEREBRAL BLOOD FLOW IN THE BRAIN | THE UNIVERSITY OF VERMONT (US) | 2020-10-01 | — | — | WO | claimed |
| US-10752606-B2 | Methods for treating protozoan infections | NEOCULI PTY LTD. (AU) | 2020-08-25 | — | — | US | claimed |
| US-20020090353-A1 | Therapeutic modulation of the tumor inflammatory response | IMUNAR CORPORATION | 2002-07-11 | — | — | US | claimed |
| WO-2002030408-A2 | COMPOSITIONS COMPRISING PHOSPHOLIPASE C INHIBITORS AND METHODS FOR ENHANCING PARACELLULAR PERMEABILITY ACROSS EPITHELIAL AND ENDOTHELIAL BARRIERS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2002-04-18 | — | — | WO | claimed |
| US-6028209-A | REACTING A FATTY ALCOHOL WITH PHOSPHORUS OXYCHLORIDE IN A SINGLE VESSEL PROCESS, THEN REACTING WITH CHOLINE SALT TO FORM PHOSPHORIC ACID DIESTER CHLORIDE, HYDROLYSIS AND ISOLATION | ASTA MEDICA AG (DE) | 2000-02-22 | — | — | US | claimed |
| US-5942639-A | REACTING A C14-C18 N-ALKANOL WITH PHOSPHORUS OXYCHLORIDE THEN REACTING THE PRODUCT WITHOUT ISOLATION OR PURIFICATION WITH A CHOLINE SALT IN THE PRESENCE OF A BASE TO FORM THE PHOSPHORIC ACID DIESTER CHLORIDE, HYDROLYSING; MIXED BED ION EXCHANGING | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1999-08-24 | — | — | US | claimed |
| EP-0858807-A2 | Use of dopamine receptor antagonists in palliative tumor therapy | ASTA Medica Aktiengesellschaft (DE) | 1998-08-19 | — | — | EP | claimed |
| EP-0521297-B1 | Process for the preparation of alkylphosphocholines and purification thereof | ASTA MEDICA AG (DE) | 1997-09-17 | — | — | EP | claimed |
| EP-0593897-B1 | Stabilized solutions of alkylphosphocholine in glycerolalkylether | ASTA MEDICA AG (DE) | 1996-04-17 | — | — | EP | claimed |
| US-5446033-A | Antitumor agent; storage stability, antiseptic, chemical resistance, by-product inhibition | ASTA MEDICA AG (DE) | 1995-08-29 | — | — | US | claimed |
| EP-0593897-A1 | Stabilized solutions of alkylphosphocholine in glycerolalkylether | ASTA Medica Aktiengesellschaft (DE) | 1994-04-27 | — | — | EP | claimed |
| EP-0521297-A1 | Process for the preparation of alkylphosphocholines and purification thereof | ASTA Medica Aktiengesellschaft (DE) | 1993-01-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096643-A1 | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates And Their Preparation | PHOSPHO1, PCTP, SGMS1 | MEN1 899/4885KMT2A 1288/4885CYP1A2 4247/4885 |
| US-20220389160-A1 | EFFECTIVE INTRANASAL DELIVERY TO BRAIN | ADCYAP1R1, PCNP, CNP | MEN1 279/4885KMT2A 3068/4885CYP1A2 1284/4885 |
| US-10752606-B2 | Methods for treating protozoan infections | DPM1, ABCB11, PIGS | MEN1 504/4885KMT2A 2912/4885CYP1A2 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.